Literature DB >> 3264932

Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide.

K Bendtzen1, N Morling, A Fomsgaard, M Svenson, B Jakobsen, N Odum, A Svejgaard.   

Abstract

The production of tumour necrosis factor (TNF) and interleukin 1 (IL-1) by lipopolysaccharide-activated mononuclear cells from 39 healthy donors was studied in vitro by bioassay and ELISA. The donors were typed for HLA-A, -B, -C, -DR, and -DP antigens. There was no detectable production of TNF beta (lymphotoxin). The intracellular levels of bioactive TNF alpha were minimal or undetectable in all cases. Cells from HLA-DR2+ individuals secreted significantly lower amounts of TNF alpha than cells from HLA-DR2- donors [2 ng/ml (1.5-4.4) and 7.5 ng/ml (3.9-8.3) respectively (medians 25-75%); P less than 0.01]. The difference disappeared if the cells were preactivated for 2 days with 1000 U/ml of recombinant gamma interferon (rIFN-gamma). In some individuals, the TNF alpha response increased considerably after IFN-gamma priming, in particular in those possessing the HLA-DR2 antigen. In contrast, there was no detectable difference in the production of IL-1 beta between the donors, and the IL-1 beta response decreased significantly after rIFN-gamma priming in HLA-DR2+ individuals [2.3 ng/ml (1.1-8.4) versus 7.2 ng/ml (5-7.9); P less than 0.05] and in HLA-DR2- individuals [3 ng/ml (1.1-5.3) versus 5.7 ng/ml (3.9-7.5); P less than 0.01]. There was no correlation between the TNF alpha and IL-1 responses and any of the other HLA-DR, -DP, or -B antigens. There was a significant positive correlation between the levels of TNF alpha measured by ELISA and by cytotoxicity assay. However, the TNF alpha-containing supernatants from 9 out of 37 individuals appeared to contain inhibitor(s) of the biological activity of TNF alpha. The presence of inhibitor(s) was not associated with any HLA antigens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264932     DOI: 10.1111/j.1365-3083.1988.tb01492.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  28 in total

Review 1.  Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis.

Authors:  C L Verweij
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  [Tissue typing in perforating corneal transplantation].

Authors:  J Wachtlin; R Khaireddin; F Hoffmann
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  Haplotypic polymorphisms of the TNFB gene.

Authors:  L J Abraham; D C Du; K Zahedi; R L Dawkins; A S Whitehead
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 4.  MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune diseases.

Authors:  C O Jacob; G D Lewis; H O McDevitt
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  Cytokines suppress human islet function irrespective of their effects on nitric oxide generation.

Authors:  D L Eizirik; S Sandler; N Welsh; M Cetkovic-Cvrlje; A Nieman; D A Geller; D G Pipeleers; K Bendtzen; C Hellerström
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

6.  Novel compound tetra-, dinucleotide microsatellite polymorphism in the tumor necrosis factor/lymphotoxin locus.

Authors:  S J Greenberg; K Fujihara; S M Selkirk; F Yu; T L Du; N Glenister; P Hohmann; M H Rickert; P O Spence; C E Miller; L D Jacobs
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

7.  Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis.

Authors:  E L Kaijzel; M V van Krugten; B M Brinkman; T W Huizinga; T van der Straaten; J M Hazes; H W Ziegler-Heitbrock; S A Nedospasov; F C Breedveld; C L Verweij
Journal:  Mol Med       Date:  1998-11       Impact factor: 6.354

8.  Genetic markers in clinically well defined patients with ulcerative colitis (UC).

Authors:  G Bouma; J B Crusius; M A García-González; B U Meijer; H P Hellemans; R J Hakvoort; G M Schreuder; P J Kostense; S G Meuwissen; A S Peña
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

9.  Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor.

Authors:  M Jasiński; J Wieckiewicz; I Ruggiero; A Pituch-Noworolska; M Zembala
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  Allele-specific quantification of TNFA transcripts in rheumatoid arthritis.

Authors:  B M Brinkman; T W Huizinga; F C Breedveld; C L Verweij
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.